 |
|
Circulating Levels of Vasoactive Intestinal Polypeptide in Liver Disease
Steve Hunt, MD;
Carlos A. Vaamonde, MD;
Teresa Rattassi, MD;
M. Gregg Berian, MD;
Sami I. Said, MD;
Solomon Papper, MD
Arch Intern Med. 1979;139(9):994-996.
Abstract
In animals, the effects of vasoactive intestinal polypeptide (VIP) include peripheral vasodilation, hyperdynamic circulation, hyperglycemia, and hyperventilation. Because these phenomena are noted in patients with cirrhosis, it has been postulated that VIP might be escaping hepatic inactivation and entering the systemic circulatory system and contributing to these abnormalities. The major purpose of this study is to establish whether or not VIP levels are elevated in patients with cirrhosis. Additional goals are to determine if VIP levels are elevated in acute liver disease and in chronic illnesses with secondary liver involvement. The data demonstrate that patients with cirrhosis and those with acute liver disease or chronic illnesses with secondary hepatic involvement have a wide range of VIP levels with mean values significantly above that of normal individuals and patients with chronic illness and no liver involvement.
(Arch Intern Med 139:994-996, 1979)
Author Affiliations
From the Oklahoma City Veterans Administration (VA) Hospital and the Department of Medicine of the University of Oklahoma, Oklahoma City (Drs Hunt and Papper); the Miami VA Hospital and the Department of Medicine at the University of Miami (Drs Vaamonde, Rattassi, and Berian); and the Dallas VA Hospital and the Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical School, Dallas (Dr Said).
Footnotes
Accepted for publication Feb 19, 1979.
Reprint requests to Department of Medicine, University of Oklahoma Health Sciences Center, PO Box 26901, Oklahoma City, OK 73190 (Dr Papper).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
